Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

By sjmartinez • September 22, 2024

Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024 Sep 15:S0923-7534(24)03910-3. doi: 10.1016/j.annonc.2024.08.2330. Epub ahead of print. PMID: 39306585.

Tags: Hematology/Oncology, immunotherapy, melanoma, pembrolizumab, Phase III, Programmed cell death protein 1, Publications

Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosis

Martínez LE, Comin-Anduix B, Güemes-Aragon M, Ibarrondo J, Detels R, Mimiaga MJ, Epeldegui M. Characterization of unique B-cell populations in the circulation of people living[...]

Correlation of needle biopsy-acquired histopathologic grade of hepatocellular carcinoma with outcomes after thermal ablation

Chiang J, Raman SS, Ramakrishnan A, Keshavarz P, Sayre J, McWilliams JP, Finn RS, Agopian VG, Choi G, Lu DSK. Correlation of needle biopsy-acquired histopathologic[...]

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif[...]